{
    "root": "33f397b8-d161-6db8-e063-6294a90a532f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Omeprazole",
    "value": "20250429",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, ANHYDROUS",
            "code": "22ADO53M6F",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37586"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_25219"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50821"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "MAGNESIUM HYDROXIDE",
            "code": "NBZ3QY004S",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_35149"
        },
        {
            "name": "POLYETHYLENE GLYCOL 6000",
            "code": "30IQX730WE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ALCOHOL (100000 MW)",
            "code": "949E52Z6MY",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "POLYVINYL ALCOHOL GRAFT POLYETHYLENE GLYCOL COPOLYMER (3:1; 45000 MW)",
            "code": "23ZQ42JZZH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "RAW SUGAR",
            "code": "8M707QY5GH"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32035"
        },
        {
            "name": "AMMONIA",
            "code": "5138Q19F1X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16134"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "OMEPRAZOLE",
            "code": "KG60484QX9",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7772"
        }
    ],
    "indications": {
        "text": "omeprazole delayed-release capsules proton pump inhibitor ( ppi ) indicated : treatment active duodenal ulcer adults ( 1.1 ) eradication helicobacter pylori reduce risk duodenal ulcer recurrence adults ( 1.2 ) treatment active benign gastric ulcer adults ( 1.3 ) treatment symptomatic gastroesophageal reflux disease ( gerd ) patients 2 years age older ( 1.4 ) treatment erosive esophagitis ( ee ) due acid-mediated gerd patients 2 years age older ( 1.5 ) maintenance healing ee due acid-mediated gerd patients 2 years age older ( 1.6 ) pathologic hypersecretory conditions adults ( 1.7 )",
        "doid_entities": [
            {
                "text": "duodenal ulcer (DOID:1724)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1724"
            },
            {
                "text": "gastric ulcer (DOID:10808)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10808"
            },
            {
                "text": "gastroesophageal reflux (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "esophagitis (DOID:11963)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11963"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "indication recommended adult ( 2.1 ) pediatric ( 2.2 ) treatment active duodenal ulcer 20 mg daily 4 weeks ; patients may require additional 4 weeks ( 2.1 ) h. pylori eradication reduce risk duodenal ulcer recurrence triple therapy : omeprazole 20 mg twice daily 10 days ( 2.1 ) * amoxicillin 1000 mg clarithromycin 500 mg dual therapy : omeprazole 40 mg daily 14 days * * clarithromycin 500 mg three times daily 14 days ( 2.1 ) active benign gastric ulcer 40 mg daily 4 8 weeks ( 2.1 ) symptomatic gerd 20 mg daily 4 weeks ( 2.1 ) full prescribing information weight based dosing pediatric patients 2 years age older ( 2.2 ) ee due acid-mediated gerd 20 mg daily 4 8 weeks ( 2.1 ) * * * full prescribing information weight based dosing pediatric patients 2 years age older ( 2.2 ) maintenance healing ee due acid-mediated gerd 20 mg daily ( 2.1 ) * * * * full prescribing information weight based dosing pediatric patients 2 years age older ( 2.2 ) pathological hypersecretory conditions starting dose 60 mg daily ( varies individual patient , full prescribing information ) long clinically indicated ( 2.1 ) * ulcer present , continue omeprazole delayed-release capsules 20 mg daily additional 18 days . * * ulcer present , continue omeprazole delayed-release capsules 20 mg daily additional 14 days . * * * additional 4 weeks treatment may given response ; recurrence additional 4 8 week courses may considered . * * * * studied 12 months . reduce 10 mg daily patients hepatic impairment ( child pugh class , b , c ) asian patients ( 8.6 , 8.7 )",
        "doid_entities": [
            {
                "text": "duodenal ulcer (DOID:1724)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1724"
            },
            {
                "text": "gastric ulcer (DOID:10808)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10808"
            },
            {
                "text": "gerd (DOID:8534)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8534"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "omeprazole delayed-release capsules , usp , 20 mg , white body black printing `` 20 `` white cap black printing \u201c xi \u201d . supplied follows : ndc 51407-641-01 , bottle 100 capsules ( desiccant ) ndc 51407-641-10 , bottle 1000 capsules ( desiccant ) ndc 51407-813-30 , bottle 30 capsules ( desiccant ) ndc 51407-813-90 , bottle 90 capsules ( desiccant ) ndc 51407-813-01 , bottle 100 capsules ( desiccant ) ndc 51407-813-10 , bottle 1000 capsules ( desiccant ) storage store omeprazole delayed-release capsules , usp tight container protected light moisture . store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "omeprazole delayed-release capsules contraindicated patients known hypersensitivity including anaphylaxis formulation [ ( 5.2 ) ] substituted benzimidazoles . hypersensitivity may include anaphylaxis , anaphylactic shock , angioedema , bronchospasm , acute tubulointerstitial nephritis , urticaria [ ( 5.2 ) , ( 6 ) ] . proton pump inhibitors ( ppis ) , including omeprazole , contraindicated patients receiving rilpivirine-containing products [ ( 7 ) ] . information antibacterial agents ( clarithromycin amoxicillin ) indicated combination omeprazole , refer section package inserts .",
    "indications_original": "Omeprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated for the: Treatment of active duodenal ulcer in adults ( 1.1 ) Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence in adults ( 1.2 ) Treatment of active benign gastric ulcer in adults ( 1.3 ) Treatment of symptomatic gastroesophageal reflux disease (GERD) in patients 2 years of age and older ( 1.4 ) Treatment of erosive esophagitis (EE) due to acid-mediated GERD in patients 2 years of age and older ( 1.5 ) Maintenance of healing of EE due to acid-mediated GERD in patients 2 years of age and older ( 1.6 ) Pathologic hypersecretory conditions in adults ( 1.7 )",
    "contraindications_original": "Indication Recommended Adult ( 2.1 ) and Pediatric Dosage ( 2.2 ) Treatment of Active Duodenal Ulcer 20 mg once daily for 4 weeks; some patients may require an additional 4 weeks ( 2.1 ) H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Omeprazole 20 mg Each drug twice daily for 10 days ( 2.1 )* Amoxicillin 1000 mg Clarithromycin 500 mg Dual Therapy: Omeprazole 40 mg once daily for 14 days** Clarithromycin 500 mg three times daily for 14 days ( 2.1 ) Active Benign Gastric Ulcer 40 mg once daily for 4 to 8 weeks ( 2.1 ) Symptomatic GERD 20 mg once daily for up to 4 weeks ( 2.1 ) See full prescribing information for weight based dosing in pediatric patients 2 years of age and older ( 2.2 ) EE due to Acid-Mediated GERD 20 mg once daily for 4 to 8 weeks ( 2.1 ) *** See full prescribing information for weight based dosing in pediatric patients 2 years of age and older ( 2.2 ) Maintenance of Healing of EE due to Acid-Mediated GERD 20 mg once daily ( 2.1 ) **** See full prescribing information for weight based dosing in pediatric patients 2 years of age and older ( 2.2 ) Pathological Hypersecretory Conditions Starting dose is 60 mg once daily (varies with individual patient, see full prescribing information) as long as clinically indicated ( 2.1 ) *if ulcer present, continue omeprazole delayed-release capsules 20 mg once daily for an additional 18 days. **if ulcer present, continue omeprazole delayed-release capsules 20 mg once daily for an additional 14 days. ***an additional 4 weeks of treatment may be given if no response; if recurrence additional 4 to 8 week courses may be considered. ****studied for 12 months. Reduce the dosage to 10 mg once daily for patients with hepatic impairment (Child Pugh Class A, B, or C) and Asian patients ( 8.6 , 8.7 )",
    "warningsAndPrecautions_original": "Omeprazole delayed-release capsules, USP, 20 mg, are white body with black printing \"20\" and white cap with black printing \u201cXI\u201d. They are supplied as follows:\n                  NDC 51407-641-01, bottle of 100 capsules (with desiccant)\n                  NDC 51407-641-10, bottle of 1000 capsules (with desiccant)\n                  NDC 51407-813-30, bottle of 30 capsules (with desiccant)\n                  NDC 51407-813-90, bottle of 90 capsules (with desiccant)\n                  NDC 51407-813-01, bottle of 100 capsules (with desiccant)\n                  NDC 51407-813-10, bottle of 1000 capsules (with desiccant)\n                  \n                  \n                  \n                     Storage\n                  \n                  Store omeprazole delayed-release capsules, USP in a tight container protected from light and moisture. Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Omeprazole delayed-release capsules are contraindicated in patients with known hypersensitivity reactions including anaphylaxis to the formulation\n  \n   [see Warnings and Precautions (\n   \n    5.2\n                        )] or any substituted benzimidazoles. Hypersensitivity reactions may include anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, and urticaria\n  \n   [see Warnings and Precautions (\n   \n    5.2), Adverse Reactions (\n   \n    6)].\n  \n   \n                     \n                     Proton pump inhibitors (PPIs), including omeprazole, are contraindicated in patients receiving rilpivirine-containing products\n  \n   [see Drug Interactions (\n   \n    7)].\n  \n   \n                     \n                     For information about contraindications of antibacterial agents (clarithromycin and amoxicillin) indicated in combination with omeprazole, refer to the CONTRAINDICATIONS section of their package inserts.",
    "drug": [
        {
            "name": "Omeprazole",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_7772"
        }
    ]
}